Ulva pertusa Modulated Colonic Oxidative Stress Markers and Clinical Parameters: A Potential Adjuvant Therapy to Manage Side Effects During 5-FU Regimen
Alberto Repici, Anna Paola Capra, Ahmed Hasan, Rossella Basilotta, Sarah Adriana Scuderi, Michela Campolo, Irene Paterniti, Emanuela Esposito, Alessio Ardizzone · 2024
Read Ulva pertusa Modulated Colonic Oxidative Stress Markers and Clinical Parameters: A Potential Adjuvant Therapy to Manage Side Effects During 5-FU Regimen by Alberto Repici, Anna Paola Capra, Ahmed Hasan, Rossella Basilotta, Sarah Adriana Scuderi, Michela Campolo, Irene Paterniti, Emanuela Esposito, Alessio Ardizzone (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11641785.txt.
Description
Alberto Repici and co-authors fed rats a green seaweed extract and watched it soften the side effects of a workhorse chemotherapy drug, in a 2024 study. The drug, 5-FU, treats colon, breast, pancreatic, and stomach cancers but brings mouth inflammation, appetite loss, and blood count drops. Rats on two dose schedules of the drug then received the alga, Ulva pertusa, by mouth for two weeks.
Treated rats kept more weight, ate better, and had less diarrhea. Blood, kidney, and liver markers improved, and colon tissue showed calmer oxidative stress signals across a panel of measures. The authors call the seaweed a promising partner for chemotherapy, possibly letting patients tolerate treatment better. They are careful to ask for more preclinical and clinical work before any patient-facing claim.
Catalog record
| CREATOR | Alberto Repici, Anna Paola Capra, Ahmed Hasan, Rossella Basilotta, Sarah Adriana Scuderi, Michela Campolo, Irene Paterniti, Emanuela Esposito, Alessio Ardizzone |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |